Entries by Meng Ding

11 09 '25

Now Is The Right Time For A Hong Kong Biotech Listing

/in , , , , , , , /by

Hong Kong has recently emerged as the number one IPO venue globally, and one of the sectors driving this is biotech. For China-based biotechs looking to float, Hong Kong is a natural destination. But biotechs based anywhere in the world may wish to ride the current wave, as Meng Ding explains.

03 06 '24

Hong Kong’s Biotech Listings Emerge From Two-Year Downturn With 18As Booming

/in , , , , /by

Biotech and medtech startups based in the People’s Republic of China (P.R.C.) are flocking to Hong Kong to float. Meng Ding explains how a combination of listing reforms and an explosion of innovation in the Greater Bay Area have led to Hong Kong’s 18A process being popular for life sciences.